CH681425A5 - - Google Patents
Download PDFInfo
- Publication number
- CH681425A5 CH681425A5 CH3616/90A CH361690A CH681425A5 CH 681425 A5 CH681425 A5 CH 681425A5 CH 3616/90 A CH3616/90 A CH 3616/90A CH 361690 A CH361690 A CH 361690A CH 681425 A5 CH681425 A5 CH 681425A5
- Authority
- CH
- Switzerland
- Prior art keywords
- trp
- cys
- phe
- thr
- microparticles
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 19
- 239000011859 microparticle Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 238000001125 extrusion Methods 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 9
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 9
- 229920002988 biodegradable polymer Polymers 0.000 claims description 8
- 239000004621 biodegradable polymer Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 102000005157 Somatostatin Human genes 0.000 claims description 4
- 108010056088 Somatostatin Proteins 0.000 claims description 4
- 229920002253 Tannate Polymers 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 4
- 229960000553 somatostatin Drugs 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 241000234435 Lilium Species 0.000 claims description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 3
- 239000012907 medicinal substance Substances 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 claims 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 2
- ZMKVBUOZONDYBW-UHFFFAOYSA-N 1,6-dioxecane-2,5-dione Chemical compound O=C1CCC(=O)OCCCCO1 ZMKVBUOZONDYBW-UHFFFAOYSA-N 0.000 claims 1
- 229940102213 injectable suspension Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 description 9
- 230000006835 compression Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108700012941 GNRH1 Proteins 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 229920000229 biodegradable polyester Polymers 0.000 description 2
- 239000004622 biodegradable polyester Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000012438 extruded product Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH3616/90A CH681425A5 (pl) | 1990-11-14 | 1990-11-14 | |
BE9101009A BE1004923A5 (fr) | 1990-11-14 | 1991-10-31 | Procede de preparation d'une composition pharmaceutique. |
GB9123241A GB2249725B (en) | 1990-11-14 | 1991-11-01 | Biodegradable microparticles or implant containing insoluble peptide salts |
FR9113563A FR2668707B1 (fr) | 1990-11-14 | 1991-11-04 | Procede de preparation d'une composition pharmaceutique. |
CA002055115A CA2055115A1 (en) | 1990-11-14 | 1991-11-07 | A process for preparing a pharmaceutical composition |
ITBS910119A IT1252870B (it) | 1990-11-14 | 1991-11-08 | Procedimento di preparazione di una composizione farmaceutica sotto forma di microparticelle |
DE4136930A DE4136930A1 (de) | 1990-11-14 | 1991-11-11 | Verfahren zur herstellung einer pharmazeutischen zusammensetzung, die pharmazeutische zusammensetzung sowie deren verwendung |
NL9101877A NL9101877A (nl) | 1990-11-14 | 1991-11-11 | Werkwijze voor het bereiden van een farmaceutisch preparaat. |
US07/790,033 US5439688A (en) | 1989-07-28 | 1991-11-12 | Process for preparing a pharmaceutical composition |
AT0223591A AT397198B (de) | 1990-11-14 | 1991-11-12 | Verfahren zur herstellung einer zur kontinuierlichen und kontrollierten abgabe eines natürlichen oder synthetischen peptids bestimmten pharmazeutischen zusammensetzung, insbesondere in form von mikrokapseln bzw. implantaten |
SE9103348A SE506448C2 (sv) | 1990-11-14 | 1991-11-13 | Förfarande för framställning av en farmaceutisk komposition innehållande en peptid |
JP91297358A JPH04288021A (ja) | 1990-11-14 | 1991-11-13 | 薬用組成物の製造方法 |
ES09102518A ES2049617B1 (es) | 1990-11-14 | 1991-11-13 | Procedimiento de preparacion de una composicion farmaceutica. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH3616/90A CH681425A5 (pl) | 1990-11-14 | 1990-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CH681425A5 true CH681425A5 (pl) | 1993-03-31 |
Family
ID=4259807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH3616/90A CH681425A5 (pl) | 1989-07-28 | 1990-11-14 |
Country Status (12)
Country | Link |
---|---|
JP (1) | JPH04288021A (pl) |
AT (1) | AT397198B (pl) |
BE (1) | BE1004923A5 (pl) |
CA (1) | CA2055115A1 (pl) |
CH (1) | CH681425A5 (pl) |
DE (1) | DE4136930A1 (pl) |
ES (1) | ES2049617B1 (pl) |
FR (1) | FR2668707B1 (pl) |
GB (1) | GB2249725B (pl) |
IT (1) | IT1252870B (pl) |
NL (1) | NL9101877A (pl) |
SE (1) | SE506448C2 (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
US5456917A (en) * | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
US5945128A (en) * | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
WO2004096178A1 (en) * | 2003-05-02 | 2004-11-11 | The University Of Nottingham | Nano and microparticle drug delivery systems comprising polyesters containing aliphatic dicarboxylate residues and residues of aliphatic polyols |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3978203A (en) * | 1974-07-12 | 1976-08-31 | Dynatech Corporation | Sustained release of pharmaceuticals from polyester matrices |
US4481353A (en) * | 1983-10-07 | 1984-11-06 | The Children's Medical Center Corporation | Bioresorbable polyesters and polyester composites |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
CH672887A5 (pl) * | 1987-10-14 | 1990-01-15 | Debiopharm Sa | |
CH679207A5 (pl) * | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
IT1243390B (it) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
-
1990
- 1990-11-14 CH CH3616/90A patent/CH681425A5/fr not_active IP Right Cessation
-
1991
- 1991-10-31 BE BE9101009A patent/BE1004923A5/fr not_active IP Right Cessation
- 1991-11-01 GB GB9123241A patent/GB2249725B/en not_active Expired - Fee Related
- 1991-11-04 FR FR9113563A patent/FR2668707B1/fr not_active Expired - Fee Related
- 1991-11-07 CA CA002055115A patent/CA2055115A1/en not_active Abandoned
- 1991-11-08 IT ITBS910119A patent/IT1252870B/it active IP Right Grant
- 1991-11-11 NL NL9101877A patent/NL9101877A/nl active Search and Examination
- 1991-11-11 DE DE4136930A patent/DE4136930A1/de not_active Ceased
- 1991-11-12 AT AT0223591A patent/AT397198B/de not_active IP Right Cessation
- 1991-11-13 SE SE9103348A patent/SE506448C2/sv not_active IP Right Cessation
- 1991-11-13 JP JP91297358A patent/JPH04288021A/ja active Pending
- 1991-11-13 ES ES09102518A patent/ES2049617B1/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ITBS910119A0 (it) | 1991-11-08 |
SE9103348D0 (sv) | 1991-11-13 |
FR2668707B1 (fr) | 1995-05-24 |
IT1252870B (it) | 1995-06-28 |
GB2249725A (en) | 1992-05-20 |
GB9123241D0 (en) | 1991-12-18 |
NL9101877A (nl) | 1992-06-01 |
SE9103348L (sv) | 1992-05-15 |
BE1004923A5 (fr) | 1993-02-23 |
ES2049617B1 (es) | 1997-03-16 |
SE506448C2 (sv) | 1997-12-15 |
ITBS910119A1 (it) | 1993-05-08 |
AT397198B (de) | 1994-02-25 |
ATA223591A (de) | 1993-07-15 |
JPH04288021A (ja) | 1992-10-13 |
FR2668707A1 (fr) | 1992-05-07 |
CA2055115A1 (en) | 1992-05-15 |
DE4136930A1 (de) | 1992-08-20 |
GB2249725B (en) | 1994-08-10 |
ES2049617A1 (es) | 1994-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH679207A5 (pl) | ||
US5439688A (en) | Process for preparing a pharmaceutical composition | |
US5225205A (en) | Pharmaceutical composition in the form of microparticles | |
RU2131244C1 (ru) | Твердая дозированная форма | |
DE69032976T2 (de) | Zubereitung von pharmazeutischen und anderen matrixsystemen durch auflösung in festem zustand | |
DE69102176T2 (de) | Stabile Zusammensetzungen zur parenteralen Anwendung und Verfahren zu ihrer Herstellung. | |
JP2571790B2 (ja) | 非経口投与のための組成物及びその使用 | |
FR2665360A1 (fr) | Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues. | |
JP2000505429A (ja) | 揮発性塩を用いた可溶性デリバリーシステムの製造方法 | |
EP0621777A1 (de) | Wirkstoff-enthaltende festkörper mit einem gerüst aus hydrophilen makromolekülen und verfahren zu ihrer herstellung. | |
CH681425A5 (pl) | ||
KR20060109479A (ko) | 제약상 다입자의 제조 방법 | |
EP0440702B1 (en) | A pharmaceutical composition for rapid release of the active component comprising a solid dispersion and a surfactant | |
HUE033660T2 (en) | Spray containing fine particulate active ingredient | |
FR2515035A1 (fr) | Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication | |
CH685285A5 (fr) | Procédé de préparation d'une composition pharmaceutique contenant des sels de peptides. | |
DE69422806T2 (de) | Herstellung von matrizes | |
JPH0278613A (ja) | 精油含有軟カプセル | |
CA2247994A1 (en) | Solubilizing delivery systems and method of manufacture | |
Joshi et al. | Solid Dispersion: A Technology for the Improvement of Oral Bioavailability of Poorly Soluble Drugs | |
AU677198C (en) | Pharmaceutical and other dosage forms | |
FR2702375A1 (fr) | Microcapsules à libération progressive, leur procédé de préparation et compositions pharmaceutiques ou vétérinaires les contenant. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |